Coronavirus company news summary – EC signs a supply deal with CureVac – Pfizer,BioNTech report positive data from Covid-19 vaccine candidate

21 August 2020 (Last Updated August 21st, 2020 09:00)

21 August 2020 

Germany-based CureVac and the European Commission (EC) have concluded exploratory discussions on an Advanced Purchase Agreement (APA) for the company’s mRNA-based Covid-19 vaccine candidate. The proposed deal will provide all European Union Member States with up to 225 million doses, along with an option for an additional 180 million doses.

Pfizer and BioNTech have reported positive early safety and immunogenicity data from the Phase I clinical trial of their second Covid-19 vaccine candidate, BNT162b2, in the US. Data showed that 30μg of BNT162b2, seven days after the second dose, induced SARS-CoV-2-neutralising geometric mean titers (GMTs) in younger and older adults. The vaccine candidate was well tolerated across all populations.

Oragenics signed a process development and drug substance manufacturing agreement with Avid Bioservices for its potential Covid-19 vaccine, Terra CoV-2. Avid will offer analytical method development, process development and drug substance manufacturing services to Oragenics. The companies will begin the initial phase of the project immediately.

Russia’s Covid-19 vaccine candidate, Sputnik V, will be tested in more than 40,000 participants in a clinical trial that is scheduled to start next week, according to Reuters. Prior small-scale studies found the candidate to be safe and effective. Meanwhile, a senior Mexican government official said that the country will receive at least 2,000 doses of Sputnik V for trials in its population.

Indonesia's PT Bio Farma has entered into an agreement with China-based Sinovac Biotech for up to 40 million doses of the latter’s Covid-19 vaccine candidate, which will be supplied from November 2020 to March 2021. Indonesia has been evaluating the candidate in a Phase III clinical trial in the West Java provincial capital of Bandung.